title: Prospective clinical trial of gelatin-thrombin matrix as first line treatment of posterior epistaxis.
abstract: OBJECTIVE
  To evaluate the effectiveness of gelatin-thrombin matrix for first line treatment of posterior epistaxis. Secondarily, we evaluated discomfort during treatment and the cost savings of treatment with gelatin-thrombin matrix compared to posterior packing, endoscopic, or endovascular treatment at our institution.
  
  
  METHODS
  Prospective pilot, nonblinded, noncontrolled registered clinical trial (NCT01098578).
  
  
  METHODS
  Twenty patients with posterior epistaxis were enrolled into this study. Gelatin-thrombin matrix was used for posterior epistaxis treatment with simultaneous ipsilateral choanal occlusion. Patients were discharged within 2 hours of being successfully treated. A visual analog scale (range 0-10) was used to assess treatment discomfort. Patients were evaluated in clinic 5 and 30 days after treatment to assess for intranasal complications and recurrent epistaxis.
  
  
  RESULTS
  Gelatin-thrombin matrix successfully treated epistaxis in 80% of the patients. The procedure was associated with a mean discomfort of 3.6 (range 0-9.7). The institutional per case cost of treatment of patients with posterior epistaxis with gelatin-thrombin matrix is 80.3%, 87.4%, and 89.4% less than with endoscopic surgery, posterior packing, or embolization, respectively. There were no complications.
  
  
  CONCLUSIONS
  This pilot study demonstrated that gelatin-thrombin matrix is a safe and both a clinically effective and cost-saving means of treating posterior epistaxis. In this study, its use is associated with a low level of discomfort. This treatment method may improve the quality of care for patients with posterior epistaxis.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, The University of Ottawa, Ottawa, Canada; The Ottawa Hospital, Ottawa, Canada; The Ottawa Hospital Research Institute (OHRI), Ottawa, Canada.
authors.forename: Shaun J
authors.initials: SJ
authors.lastname: Kilty
authors.forename: Mohammad
authors.initials: M
authors.lastname: Al-Hajry
authors.forename: Dakheelallah
authors.initials: D
authors.lastname: Al-Mutairi
authors.forename: James P
authors.initials: JP
authors.lastname: Bonaparte
authors.forename: Melanie
authors.initials: M
authors.lastname: Duval
authors.forename: Euna
authors.initials: E
authors.lastname: Hwang
authors.forename: Darren
authors.initials: D
authors.lastname: Tse
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004724:Endoscopy; D057510:Endovascular Procedures; D004844:Epistaxis / Q000628:therapy*; D005260:Female; D005780:Gelatin / Q000627:therapeutic use*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D013917:Thrombin / Q000627:therapeutic use*
chemical_list: D006490:Hemostatics; D005780:Gelatin; D013917:Thrombin
keywords: Gelatin-thrombin matrix; clinical trial